1
|
Sarmiento M, Rojas P, Triantafilo N, Campbell J, García MJ, Ocqueteau M, Sandoval V, Rojas A, Gazmuri JT, Guerrero G, Vergara M, Bertin P, Ramírez P, Jara V, Gutiérrez C, Soto K, Arellano S, Pizarro I, Lorca C. [Age does not affect the outcome of allogeneic hematopoietic precursor transplantation for acute myeloid leukemia]. Rev Med Chil 2021; 149:22-29. [PMID: 34106132 DOI: 10.4067/s0034-98872021000100022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2020] [Accepted: 11/23/2020] [Indexed: 11/17/2022]
Abstract
BACKGROUND In our country, transplantation centers differ in the age limit for allogeneic hematopoietic transplantation (ALOHT). In our program, transplants with age- adjusted conditioning are performed in patients until 70 years old. Currently more than 60% of ALOHT reported to the Center for International Bone Marrow Transplantation Research (CIBMTR) are performed in patients older than 40 years. AIM To report our experience with ALOHT in acute myelogenous leukemia (AML), analyzing patient age at transplantation in different periods and transplant results in different age groups. MATERIAL AND METHODS A retrospective analysis of the database of adult hematopoietic transplants in AML patients was performed. Demographic data, disease characteristics, transplant data, survival and relapse times, and mortality were collected. RESULTS In our program, 1030 transplants were performed in adults and 119 ALOHT were performed in AML patients, between 1990 and 2020. The median age of patients in all periods was 41 years, (range 16-69). The median age was 33 and 45 years, in the periods 1990-2000 and 2000-2020 respectively (p < 0.01). Seventy-eight patients received myeloablative conditioning (median age 44 years) and 41 reduced intensity conditioning (median age 53 years). Five-year overall survival was 44.6% (confidence intervals (CI) 41-48). Non relapse mortality of all periods was 19% (CI 17 - 40%) and relapse rate was 17 % (CI 16-22). No difference in five years overall survival among patients younger than 40, 41 to 50 and over 51 years was observed. CONCLUSIONS Overall Survival, non-relapse mortality and relapse rate were similar in younger and older patients in our program and similar to those previously reported in other centers.
Collapse
Affiliation(s)
- Mauricio Sarmiento
- Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Patricio Rojas
- Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Nicolás Triantafilo
- Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - James Campbell
- Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - María José García
- Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Mauricio Ocqueteau
- Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Vicente Sandoval
- Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Andrés Rojas
- Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - José Tomás Gazmuri
- Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Gonzalo Guerrero
- Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Maximiliano Vergara
- Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Pablo Bertin
- Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Pablo Ramírez
- Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Verónica Jara
- Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Catherine Gutiérrez
- Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Katherine Soto
- Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Silvana Arellano
- Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Isabel Pizarro
- Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Carla Lorca
- Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
| |
Collapse
|